Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DYN101

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Perceptive Advisors

            Deal Size: $54.6 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing April 02, 2020


            Funding supports ongoing Phase 1 / 2 'Unite-CNM' study of DYN101 in Patients with Myotubular and Centronuclear Myopathies.